{"entity":{"id":"nct06925737","kind":"trial","name":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","aka":["IDeate-Prostate01"],"tldr":"A phase 3 trial of Ifinatamab deruxtecan, Docetaxel, Prednisone in prostate cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) is a phase 3 interventional study registered as NCT06925737 by Merck Sharp & Dohme LLC, with 1440 participants planned, started 2025-05-13 and due to reach its primary completion in 2028-06-26. Interventions recorded: Ifinatamab deruxtecan, Docetaxel, Prednisone, Rescue Medication. Conditions listed: Prostate Cancer, Prostatic Neoplasms. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06925737","url":"https://clinicaltrials.gov/study/NCT06925737"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":["adc","cytotoxic-chemotherapy"],"targets":[],"drugs":["ifinatamab-deruxtecan","docetaxel","prednisone"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06925737","phase":"3","setting":"A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT06925737","source":"https://clinicaltrials.gov/study/NCT06925737","fetchedAt":"2026-10-07T16:55:18.467Z","studySha256":"3c596a1b6c719c13af35df2103b5d537da6e834475a0b53435fd4eb03a99837f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":1,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":1440,"enrolmentType":"ESTIMATED","siteCount":298,"recruitingSiteCount":287,"countries":["Argentina","Australia","Austria","Brazil","Chile","China","Colombia","Czechia","Denmark","France","Germany","Greece","Guatemala","Hong Kong","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Norway","Peru","Poland","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2025-05-13","startedType":"actual","enrolled":1440,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06925737/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"ifinatamab-deruxtecan","kind":"drug","name":"Ifinatamab deruxtecan","route":"/drugs/ifinatamab-deruxtecan/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}